Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 3;28(8):e633-e644.
doi: 10.1093/oncolo/oyad088.

Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE

Shilei Bai  1 , Pinghua Yang  2 , Jianwei Liu  1 , Hui Xue  1 , Yong Xia  3 , Fuchen Liu  4 , Zhao Yang  1 , Lei Zhang  1 , Yeye Wu  1 , Feng Shen  3 , Kui Wang  1
Affiliations

Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE

Shilei Bai et al. Oncologist. .

Abstract

Background: The aim of this study was to investigate whether postoperative adjuvant transcatheter arterial chemoembolization (TACE) treatment in wide- and narrow-margin groups could improve the long-term prognosis of patients with hepatocellular carcinoma (HCC).

Materials and methods: A total of 670 patients with HCC who underwent radical hepatectomy from January 2016 to December 2017 were enrolled, including 397 patients and 273 patients in the wide- and narrow-margin groups. Recurrence-free survival (RFS) and overall survival (OS) outcomes were compared in the wide-margin and narrow-margin groups with and without adjuvant TACE postoperatively, respectively. Propensity score matching (PSM) analysis was used to match patients between TACE and no TACE groups in a 1:1 ratio.

Results: The wide-margin resection was associated with better RFS and OS rates than narrow-margin resection for patients with HCC. Patients with postoperative adjuvant TACE had a better RFS and OS than patients without postoperative adjuvant TACE in the narrow-margin group and reduced the intrahepatic recurrence rate (39.1% vs. 52.6%, P = .036) and the local recurrence rate in the liver (11.2% vs. 21.4%, P = .032). But postoperative adjuvant TACE did not alter recurrence and survival outcomes in the wide-margin group. Similar results were noted after propensity score matching (PSM).

Conclusion: The wide-margin resection had better RFS and OS than the narrow-margin resection for patients with HCC. Postoperative adjuvant TACE was associated with reduced recurrence and improved OS after narrow-margin resection, but was not effective in the wide-margin resection.

Keywords: adjuvant TACE; hepatocellular carcinoma; prognosis; propensity score matching; surgical margin.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1.
Figure 1.
Flow chart of patient’s inclusion.
Figure 2.
Figure 2.
Kaplan-Meier analysis of recurrence-free survival (RFS) and overall survival (OS) for hepatocellular carcinoma (HCC) patients after liver resection with or without adjuvant TACE before PSM. (A-B) In the wide-margin group, tumor recurrence and OS for patients with and without adjuvant TACE. (C-D) In the narrow-margin group, tumor recurrence and OS for patients with and without adjuvant TACE.
Figure 3.
Figure 3.
Kaplan-Meier analysis of recurrence-free survival (RFS) and overall survival (OS) for hepatocellular carcinoma (HCC) patients after liver resection with or without adjuvant TACE after PSM. (A-B) In the wide-margin group, tumor recurrence and OS for patients with and without adjuvant TACE. (C-D) In the narrow-margin group, tumor recurrence and OS for patients with and without adjuvant TACE.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, et al. . Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108. 10.3322/caac.21262. - DOI - PubMed
    1. Dhir M, Melin AA, Douaiher J, et al. . a review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg. 2016;263:1112-1125. 10.1097/SLA.0000000000001556. - DOI - PubMed
    1. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. - PubMed
    1. Zhang XP, Chai ZT, Gao YZ, et al. . Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. HPB (Oxford). 2019;21:1687-1696. 10.1016/j.hpb.2019.04.014. - DOI - PubMed
    1. Esagian SM, Kakos CD, Giorgakis E, et al. . Adjuvant transarterial chemoembolization following curative-intent hepatectomy versus hepatectomy alone for hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials. Cancers (Basel). 2021; 15;13(12):2984. 10.3390/cancers13122984. - DOI - PMC - PubMed

Publication types